Viatris (Viatris) Total Liabilities : $27,218 Mil (As of Dec. 2023)

View and export this data going back to 1986. Start your Free Trial

What is Viatris Total Liabilities?

Viatris's Total Liabilities for the quarter that ended in Dec. 2023 was $27,218 Mil.

Viatris's quarterly Total Liabilities increased from Jun. 2023 ($27,851.90 Mil) to Sep. 2023 ($27,877.00 Mil) but then declined from Sep. 2023 ($27,877.00 Mil) to Dec. 2023 ($27,218.10 Mil).

Viatris's annual Total Liabilities declined from Dec. 2021 ($34,350.10 Mil) to Dec. 2022 ($28,949.90 Mil) and declined from Dec. 2022 ($28,949.90 Mil) to Dec. 2023 ($27,218.10 Mil).

Viatris Total Liabilities Historical Data

The historical data trend for Viatris's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Total Liabilities Chart

Viatris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

19,371.70

38,598.90

34,350.10

28,949.90

27,218.10

Viatris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															28,949.90	28,362.30	27,851.90	27,877.00	27,218.10

Viatris Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Viatris's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7777.4	+	(16353.5	+	847.2
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1735.7	+	504.3)
	=	27,218

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	47685.5	-	20467.4
	=	27,218

Viatris's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	7777.4	+	(16353.5	+	847.2
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1735.7	+	504.3)
	=	27,218

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	47685.5	-	20467.4
	=	27,218

Viatris Total Liabilities Related Terms

Thank you for viewing the detailed overview of Viatris's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris (Viatris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (NAS:VTRS) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

MYL:Mexico 1VTRS:Italy 0A5V:UK VIA:Germany MYL:Austria

Address

1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website

https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Executives

Andrew Cuneo	officer: See Remarks	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Xiangyang (sean) Ni	officer: President, Greater China	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Leo Frans Groothuis	director	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Scott Andrew Smith	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Elisha W Finney	director	C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
Van Der Meer Mohr Pauline	director	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Menassie Taddese	officer: See Remarks	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Robert J Coury	director, officer: Executive Chairman	BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
W Don Cornwell	director
Brian Roman	officer: Global General Counsel	1000 MYLAN BOULEVARD, CANONSBURG PA 15317
Anthony Mauro	officer: See Remarks	BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
James M Kilts	director	120 PARK AVE, NEW YORK NY 10017
Melina E Higgins	director	BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HERTFORDSHIRE X0 AL10 9UL
Ian C Read	director	PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Dillon Joellen Lyons	director	BUILDING 4, TRIDENT PLACE, MOSQUITO WAY, HATFIELD, HARTFORDSHIRE X0 AL 109UL